A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1198
Abstract: To assess circulating biomarkers as predictors of antitumor response to atezolizumab (anti‐programmed death‐ligand 1 (PD‐L1), Tecentriq) serum pharmacokinetic (PK) and 95 plasma biomarkers were analyzed in 88 patients with relapsed/refractory non‐small cell lung cancer (NSCLC)… read more here.
Keywords: circulating biomarkers; response; response atezolizumab; non small ... See more keywords